Literature DB >> 12668406

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial.

Tone Tangen Haug1, Svein Blomhoff, Kerstin Hellstrøm, Ingar Holme, Mats Humble, Hans Peter Madsbu, Jan Egil Wold.   

Abstract

BACKGROUND: Maintenance of treatment effect is important for the choice of treatment for social phobia. AIMS: To examine the effect of exposure therapy and sertraline 28 weeks after cessation of medical treatment.
METHOD: In this study 375 patients with social phobia were randomised to treatment with sertraline or placebo for 24 weeks, with or without the addition of exposure therapy. Fifty-two weeks after inclusion, 328 patients were evaluated by the same psychometric tests as at baseline and the end of treatment (24 weeks).
RESULTS: The exposure therapy group and the placebo group had a further improvement in scores on social phobia during follow-up: mean change in the Clinical Global Impression - Social Phobia overall severity score was 0.45 (95% CI 0.16-0.65, P < 0.01) for the exposure group, and 0.25 (95% CI 0.00-0.48, P < 0.05) for the placebo group. At week 52 the sertraline plus exposure group and the sertraline-alone group had a significant deterioration on the 36-item Short Form Health Survey compared with exposure alone.
CONCLUSIONS: Exposure therapy alone yielded a further improvement during follow-up, whereas exposure therapy combined with sertraline and sertraline alone showed a tendency towards deterioration after the completion of treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668406     DOI: 10.1192/bjp.182.4.312

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  20 in total

Review 1.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Anxiety in primary care.

Authors:  Kristen Hope Demertzis; Michelle G Craske
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

3.  Free, brief, and validated: Standardized instruments for low-resource mental health settings.

Authors:  Rinad S Beidas; Rebecca E Stewart; Lucia Walsh; Steven Lucas; Margaret Mary Downey; Kamilah Jackson; Tara Fernandez; David S Mandell
Journal:  Cogn Behav Pract       Date:  2015-02-01

Review 4.  New modalities of assessment and treatment planning in depression: the sequential approach.

Authors:  Giovanni A Fava; Elena Tomba
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 5.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 6.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

7.  A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Authors:  Carlos Blanco; Richard G Heimberg; Franklin R Schneier; David M Fresco; Henian Chen; Cynthia L Turk; Donna Vermes; Brigette A Erwin; Andrew B Schmidt; Harlan R Juster; Raphael Campeas; Michael R Liebowitz
Journal:  Arch Gen Psychiatry       Date:  2010-03

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 9.  An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2015-06-15       Impact factor: 13.382

10.  Chronic antidepressant treatment impairs the acquisition of fear extinction.

Authors:  Nesha S Burghardt; Torfi Sigurdsson; Jack M Gorman; Bruce S McEwen; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2012-12-20       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.